IN VITRO EFFECTS OF NALOXONE ON T-LYMPHOCYTE-DEPENDENT ANTIBACTERIAL ACTIVITY IN HEPATITIS C VIRUS (HCV) INFECTED PATIENTS AND IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS

REFERENCES

• McNicholas L. F., Martin W. R. New and experimental therapeutic roles for Naloxone and relatedopioid antagonists. Drugs 1984; 27: 81
   PubMed Web of Science ®Google Scholar
• Mehrishi J. L., Mills I. H. Opiate receptors on lymphocytes and platelets in man. Clin. Immunol. Immunophatol. 1983; 27: 240
   PubMedGoogle Scholar
• Carr D. J.J., Kim C. H., De Costa B., et al. Evidence for a δ-class opioid receptors on cells of theimmune system. Cell Immunol. 1988; 116: 44
   PubMed Web of Science ®Google Scholar
• Li M. D., Mc Allen K., Sharp B. M. Regulation of delta opioid receptor expression by anti-CD3-ε,PMA, and ionomycin in murine splenocytes and T cells. J. Leukoc. Biol. 1999; 65: 707
   PubMed Web of Science ®Google Scholar
• Lograno M. D., Daniele E., Sciorsci R. L., et al. The opioid antagonist Naloxone controls L-type calcium channelactivity. 1st world congress on calcium and vitamin D in human life. Rome 1996; 12
   Google Scholar
• Linner K., Quist H. E., Sharp B. M. Met- enkephalin-containing peptides encoded by proenkephalinA mRNA expressed in activated murine thymocyte proliferation. J. Immunol. 1995; 154: 5449
   Web of Science ®Google Scholar
• Shahabi N. A., Sharp B. M. Antiproliferative effects of delta opioids on highly purifiedCD4+ and CD8+ murine T cells. J. Pharmacol. Exp. Ther. 1995; 273: 1105
   PubMed Web of Science ®Google Scholar
• Gilmore W., Weiner L. P. Beta-endorphin enhances interleukin-2 (IL-2) production in murinelymphocytes. J. Neuroimmunol. 1988; 18: 125
   PubMed Web of Science ®Google Scholar
• Bessler H., Sztein M. B., Serrate S. A. Beta-endorphin modulation of IL-1-induced IL-2 production. Immunopharmacology 1990; 19: 5
   PubMedGoogle Scholar
• Apte R. N., Durum S. K., Oppenheim J. J. Opioids modulate interleukin-1 production and secretion by bone-marrowmacrophages. Immunol. Lett. 1990; 24: 141
   PubMed Web of Science ®Google Scholar
• Hadjipetrou-Kourounakis L., Karagounis E., Rekka E., et al. Immunosuppression by a novel analgesic-opioid agonist. Scand. J. Immunol. 1989; 29: 449
   PubMed Web of Science ®Google Scholar
• Perez-Castrillon J. L., Perez-Arellano J. L., Garcia-Palomo J. D., et al. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology 1992; 23: 57
   PubMedGoogle Scholar
• Kleiner-Martin I., Gabrilovac J. Naloxone modulates NK-cell activity of human peripheral bloodlymphomonocytes like an opioid agonist. Immunopharmacol. Immunotoxicol. 1997; 15: 179
   Google Scholar
• Freier D. O., Fuchs B. A. A mechanism of action for morphin-induced immunosuppression:corticosterone mediates morphin-induced suppression of natural killer cellactivity. J. Pharmacol. Exp. Ther. 1994; 270: 1127
   PubMed Web of Science ®Google Scholar
• Kusnecov A. W., Husband A. J., King M. G., et al. In vivo effects of β-endorphin on lymphocyte proliferationand interleukin 2 production. Brain. Behav. Immun. 1987; 1: 88
   PubMedGoogle Scholar
• Sacerdote P., di San Secondo V. E., Sirchia G., et al. Endogenous opioids modulate allograft rejection time in mice:possible relation with Th1/Th2 cytokines. Clin. Exp. Immunol. 1998; 113: 465
   PubMed Web of Science ®Google Scholar
• Marotti T., Batinic D. Enkephalins regulate in vitro antibody response of human lymphocytes. Period Biol. 1990; 92: 197
   Web of Science ®Google Scholar
• Marotti T., Haberstok H. Naloxone is an inappropiate antagonist of met-enkephalin-modulatedsuperoxide release. Brain Behav. Immun. 1992; 6: 223
   PubMed Web of Science ®Google Scholar
• Rouveix B. Opiates and immune function. Consequences on infectious diseaseswith special reference to AIDS. Therapie 1992; 47: 503
   PubMed Web of Science ®Google Scholar
• Madden J. J., Donahoe R. M., Zwemmer-Collins J., et al. Binding of Naloxone to human T lymphocytes. Biochem. Pharmacol. 1987; 36: 4103
   PubMed Web of Science ®Google Scholar
• Jirillo E., Greco B., Caradonna L., et al. Evaluation of cellular immune responses and soluble mediatorsin patients with chronic hepatitis C virus (HCV) infection. Immunopharmacol. Immunotoxicol. 1995; 17: 347
   PubMed Web of Science ®Google Scholar
• Jirillo E., Amati L., Caradonna L., et al. Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) inpatients with chronic hepatitis C before and after treatment with interferon(IFN)-α. Immunopharmacol. Immunotoxicol. 1998; 20: 1
   PubMed Web of Science ®Google Scholar
• Jirillo E., Pellegrino N. M., Piazzolla G., et al. Hepatitis C virus infection. Immune responsiveness and interferon-αtreatment. Curr. Pharmaceut. Design. 2000; 6: 159
   Web of Science ®Google Scholar
• Amati L., Caradonna L., Jirillo E., et al. Immunological disorders in inflammatory bowel disease and immunotherapeuticimplications. Ital. J. Gastroenterol. Hepatol. 1999; 31: 313
   PubMedGoogle Scholar
• Caradonna L., Amati L., Lella P., et al. Phagocytosis, killing, lymphocyte-mediated antibacterial activity,serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am. J. Gastroenterol. 2000; 95: 1695
   Web of Science ®Google Scholar
• Barcellini W., Sacerdote P., Borghi M. O., et al. β-endorphin content in HIV-infected HVT78 cell line andin peripheral lymphocytes from HIV-positive subjects. Peptides 1994; 15: 769
   PubMed Web of Science ®Google Scholar
• Yamamoto H., Morise K., Kusugami K., et al. Abnormal neuropeptide concentration in rectal mucosa of patientswith inflammatory bowel disease. J. Gastroenterol. 1996; 31: 525
   PubMed Web of Science ®Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest. 1968; 21(suppl. 97)77
   PubMed Web of Science ®Google Scholar
• Kumagai K., Itoh K., Hinuma S., et al. Pretreatment of plastic Petri dishes with foetal calf serum.A simple method for macrophage isolation. J. Immunol. Meth. 1979; 29: 17
   PubMed Web of Science ®Google Scholar
• Antonaci S., Tortorella C., De Simone C., et al. Role of bacterial lipopolysaccharides in the development ofnatural antibacterial activity mediated by human peripheral blood T lymphocytes. Intern. Rev. Immunol. 1990; 6: 237
   PubMedGoogle Scholar
• Imboden J., Weiss A. The T-cell antigen receptor regulates sustained increases incytoplasmic free Ca2+ through extracellular Ca2+mobilization. Biochemistry 1987; 247: 695
   Google Scholar
• Weiss A., Imboden J., Shoback D. Role of T3 surface molecules in human T cell activation: T3-dependentactivation results in an increase in cytoplasmic free Ca2+. Proc. Natl. Acad. Sci. USA 1984; 81: 4169
   PubMed Web of Science ®Google Scholar
• Gelfand E. W., Mills G. B., Cheung R. K. Role of membrane potential in the regulation of lecitin-inducedcalcium uptake. J. Cell Physiol. 1984; 122: 533
   Google Scholar
• Gelfand E. W. Cytosolic calcium changes during T- and B-lymphocyte activation:Biological consequences and significance. Curr. Top. Membr. Transp. 1990; 35: 153
   Google Scholar
• Nesic D., Jhaver K., Vukmanovicis G. The role of protein kinase C in CD8+ T lymphocyte effector responses. J. Immunol. 1997; 159: 582
   PubMed Web of Science ®Google Scholar
• Yoshida R., Sanchez-Bueno A., Yamamoto N., et al. Ca2+-dependent Fas- and perforin-independentapoptotic death of allografted tumor cells by a type of activated macrophage. J. Immunol. 1997; 159: 15
   PubMed Web of Science ®Google Scholar
• Macho A., Hirsch T., Marzo I., et al. Glutathione depletion is an early and calcium elevation is alate event of thymocyte apoptosis. J. Immunol. 1997; 158: 4612
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J., Steinberg T. H., Allen P. M. Selective loss of the calcium ion signaling pathway in T cellsmaturing toward a T helper 2 phenotype. J. Immunol. 1997; 159: 1160
   PubMed Web of Science ®Google Scholar